DRAGARWQ5,301.00

Dr Agarwals Eye Hospital Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue from Operations319.3397.2470.9
Other Income5.05.15.8
Total Income324.3402.2476.7
Expenses
+ Purchases of Stock-in-Trade36.043.147.7
+ Employee Benefit Expense63.878.391.7
+ Finance Costs7.213.411.9
+ Depreciation & Amortisation26.639.545.6
+ Other Expenses45.557.471.0
Total Expenses262.0331.5383.1
EBITDA91.1118.5145.3
EBIT64.579.199.7
Profit
Pretax Income62.370.793.6
+ Current Tax10.110.1
+ Deferred Tax10.110.110.1
Tax Expense15.916.123.5
Net Income46.454.770.1
+ Other Comprehensive Income0.20.0
Total Comprehensive Income46.454.870.1
Per Share
Basic EPS98.64116.28147.02
Diluted EPS98.64116.28147.02
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit283.4354.0423.1
Gross Margin %88.7489.1589.86
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.